logo-loader
viewLexagene Holdings Inc.

Full interview: LexaGene hits milestone by having pre-commercial device in hospital testing

LexaGene (CVE: LXG- OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company now has one of their devices that tests for COVID-19 and other respiratory pathogens being used at the Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire.

Regan talks about the lab it is being tested in and some of the key metrics they are looking for.

Quick facts: Lexagene Holdings Inc.

Price: 0.86 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc. named herein, including the promotion by the Company of Lexagene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexagene adds to management team as they continue developing...

Lexagene (CVE: LXG-OTCQB: LXXGF) CEO Jack Regan joined Steve Darling from Proactive Vancouver to discuss the company adding a new member to their management team as they continue to move towards bringing their testing technology to market. Regan also gave Proactive an update on another part...

on 1/4/20

2 min read